Huntington's Disease Care Education and Research Center: Clinical Trials

Huntington’s Disease Clinical Trials

Active, Currently Enrolling:

  • Enroll-HD is a worldwide observational study for family members affected by Huntington’s disease, including spouses. Participants attend an annual study session at where they undergo a series of movement, behavioral and task-oriented tests, as well as a quality-of-life evaluation. Participants also may choose to donate a small volume of blood.​
     

Active, Not Enrolling:

  • ARC-HD will gauge safety and side effects of the investigational drug SD-809 ER (Extended Release) in subjects who currently take tetrabenazine, the only FDA-approved treatment for reducing involuntary body movements or chorea. This 14-month clinical trial is open to those with Huntington’s disease who currently take tetrabenazine, as well as roll-over subjects from the First-HD trial. 
     
  • PRIDE-HD will test the effectiveness of an investigational drug called pridopidine on movement, thinking and behavior, as well as gauge safety and side effects. This is a randomized, double-blind study in which some participants receive pridopidine while others get a placebo. The study is open to anyone age 21 years or older who has Huntington’s disease. 
     
  • SIGNAL-HD is designed to assess the safety, tolerability, and effectiveness of VX15, a novel monoclonal antibody in people with late prodromal or early manifest Huntington’s disease (HD). It is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study at 20 sites across the United States that seeks to enroll approximately 84 individuals, 21 or older, who are either early in the progression of the disease or are not yet diagnosed with the disease.